Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma

This is a multicenter prospective study to evaluate the efficacy and safety of chemotherapy combined with a single dose of subcutaneous(SC) injection mecapegfilgrastim on day 2 or day 5 after chemotherapy for autologous peripheral blood stem cell (PBSC) mobilization in patients with multiple myeloma or lymphoma.

Trial Details

NCT ID

NCT05294055

Phase

PHASE2

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

Etoposide
Cyclophosphamide
Mecapegfilgrastim, day 2
Mecapegfilgrastim, day 5

Locations (sample)

Hefei, Anhui, China|31.86389,117.28083
Beijing, Beijing Municipality, China|39.9075,116.39723
Zhengzhou, Henan, China|34.75778,113.64861
Jinan, Shandong, China|36.66833,116.99722
Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

Lymphoma patients with ≤2 lines of prior therapy, patients with multiple myeloma with one line of therapy;
Patients who had achieved at least partial response (PR);
Patients who were eligible for autologous peripheral blood stem cell transplantation
Age≥18 and≤65 years;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →